iGATE Research

Page 1 of 17

www.igateresearch.com

Global Alzheimers Disease Drugs Market Overview

Alzheimers disease is a devastating condition for those afflicted as well as their family
members and caregivers; the situation is only getting worse as the population ages. With the
ageing global population, the number of patients suffering from Alzheimers disease is
predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high
reward market. Drugs currently available in the market have reached maturity; patent of
leading drugs have expired. The current unmet needs represent a huge opportunity for
pharmaceutical companies which are developing targeted novel therapies.
Global Alzheimers Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global
market for Alzheimers disease drugs was dominated by Namenda and Exelon. Aricept and
Memary stands at the third and fourth spot respectively in terms of Alzheimers disease drugs
sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in
the Alzheimers disease market. With the patent expiration of popular drugs the sales of the
Alzheimers drugs has also declined. However, there are several pipeline drugs like
Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to
hit the market during the period 2017 - 2020.
Global Alzheimers Disease Country Wise Analysis: In the Alzheimers disease drugs market,
the United States is the largest market. Japan is the second leading market for Alzheimers
disease drugs market accounting for XXX% market share in 2014. China stands at the third spot
in the global Alzheimers disease drugs market being followed by India with XXX% share in the
same year. The EU5 countries together accounted for over XXX% share of the global
Alzheimers disease drugs market in 2014.
iGATE RESEARCH report titled Global Alzheimers Disease Drugs Market & Pipeline Drugs
Market Analysis to 2020 is a 150 page report with 74 Figures and 10 Tables. This report
analyses the Alzheimers Disease Drugs Market, Alzheimers Disease Pipeline Drugs Market and
Clinical Trials Analysis, Alzheimers Disease - Country Wise Drugs Market, Country Wise
Alzheimers Disease Prevalence, Major Deals in Alzheimers Disease Drugs Market Landscape,
Funding in Alzheimers Disease Drugs Research, Driving Factors and Challenges for Alzheimers
Disease Drugs Market.

iGATE Research

Page 2 of 17

www.igateresearch.com

The Alzheimers Disease Drugs Market has been analyzed from 7 View Points:
1. Alzheimers Disease - Drugs Sales and Forecast
2. Alzheimers Disease - Pipeline Drugs Sales Forecast
3. Alzheimers Disease Drugs - Country Wise Market and Forecast
4. Alzheimers Disease - Country Wise Prevalence and Forecast
5. Alzheimers Disease - Pipeline Drugs Clinical Trials Analysis
6. Alzheimers Disease - Major Deals in Alzheimers Drugs Market
7. Alzheimers Disease - Funding in Alzheimers Disease Research

The Top 9 Alzheimers Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric
The 7 Pipeline Alzheimers Disease Drugs covered in the report are as follows:
1. Solanezumab
2. ABT-126
3. idalopirdine
4. Gantenerumab
5. Crenezumab
6. Lu AE58054
7. BIIB037

iGATE Research

Page 3 of 17

www.igateresearch.com

The 9 Countries Alzheimers Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India

The Alzheimers Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports. This report is built by using
data and information sourced from Proprietary Information Database, Primary and Secondary
Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified
professionals with deep industry experience and expertise.

iGATE Research

Page 4 of 17

www.igateresearch.com

Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small
Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper,
Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on
the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report,
Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

iGATE Research

Page 5 of 17

www.igateresearch.com

About Us
iGATE RESEARCH is a global specialist in the field of Market Research, Analytics and
Consulting Services. We serve as a one stop shop for all the market and industry research needs
including Syndicated Research, Customized Research and Analytics Services. iGATE Research is
a gateway of information for various companies, whether it is Building a Strategy, or
Identifying Business Opportunity, Product Expansion, Market/Business Expansion, Competition
Assessment, etc. Combining deep understanding of the industry along with the expertise, we
help our clients in making better Business decisions.
At iGATE, we have a dedicated team of highly qualified and skilled professionals with deep
industry experience and expertise to manage complex report. We aim to offer high quality
Research Solutions to clients across multiple industries including Healthcare, Life Sciences,
Travel and Tourism, Retail, IT, Telecom, Consumer Retailing among others. We strive to
surpass our clients expectations with every single project report.
iGATE Research team is comprised of Professionals having degree in Engineering, Management
Professionals, Biotech and other experts from relevant fields. The extensive background of our
team enables us to advise clients on a range of business initiatives, product testing, Market
entry, business opportunity, formulate strategy, etc which helps them in making informed
Business decisions.

For more information Visit: www.igateresearch.com

Email: info@igateresearch.com

iGATE Research

Page 6 of 17

www.igateresearch.com

Published
By

iGATE RESEARCH
Phone: +91-858-684-0791 (India)
+91-706-527-9335 (India)
Email: info@igateresearch.com
Internet: www.igateresearch.com

Global Alzheimers Disease Drugs Market & Pipeline Drugs Market Analysis to 2020
iGATE Research Pvt. Ltd., 2015
Edition 1.0
All Rights Reserved.
No part of this Publication may be reproduced or transmitted
in any form or by any means, electronic or mechanical, including
photocopying, recording, or by any information storage
and retrieval system, without permission in
writing from the publisher.

iGATE Research

Page 7 of 17

www.igateresearch.com

Table of Contents
1.

Executive Summary

2.

Global Alzheimers Disease - Drugs Market and Prevalence Analysis

2.1

Global Alzheimers Disease - Drugs Market and Forecast (2010 - 2020)

2.2

Global Alzheimers Disease - Prevalence and Forecast (2010 - 2020)

3.

Global Alzheimers Disease - Country Wise Market Share and Forecast (2013 - 2020)

4.

Global Alzheimers Disease - Drugs Sales and Forecast To 2020

5.

4.1

Exelon (Rivastigmine) Sales and Forecast

4.2

Razadyne/Reminyl Sales and Forecast

4.3

Memary (Memantine) Sales and Forecast

4.4

Ebixa (Memantine) Sales and Forecast

4.5

Aricept (Donepezil) Sales and Forecast

4.6

Rivastach Sales and Forecast

4.7

Namenda (Memantine) Sales and Forecast

4.8

Nootropil (Piracetam) Sales and Forecast

4.9

Namzaric (Memantine and Donepezil) Sales and Forecast

Global Alzheimers Disease - Pipeline Drugs Analysis and Sales Forecast

5.1

Solanezumab Drugs Analysis and Sales Forecast

5.1.1

About Solanezumab

5.1.2

Clinical Trials

5.1.3

Solanezumab Drugs Sales Forecast

5.2

ABT-126 Drugs Analysis and Sales Forecast

5.2.1

About ABT-126

5.2.2

Clinical Trials

5.2.3

ABT-126 Drugs Sales Forecast

5.3

Idalopirdine Drugs Analysis and Sales Forecast

5.3.1

About Idalopirdine

5.3.2

Clinical Trials

5.3.3

Idalopirdine Drugs Sales Forecast

iGATE Research

Page 8 of 17

www.igateresearch.com

5.4

5.4.1

About Gantenerumab

5.4.2

Clinical Trials

5.4.3

Gantenerumab Drugs Sales Forecast

5.5

Crenezumab Drugs Analysis and Sales Forecast

5.5.1

About Crenezumab

5.5.2

Clinical Trials

5.5.3

Crenezumab Drugs Sales Forecast

5.6

Lu AE58054 Drugs Analysis and Sales Forecast

5.6.1

About Lu AE58054

5.6.2

Clinical Trials

5.6.3

Lu AE58054 Drugs Sales Forecast

5.7

6.

Gantenerumab Drugs Analysis and Sales Forecast

BIIB037 Drugs Analysis and Sales Forecast

5.7.1

About BIIB037

5.7.2

Clinical Trials

5.7.3

BIIB037 Drugs Sales Forecast

Alzheimers Disease Drugs Market and Prevalence - Country Wise Analysis

6.1

United States - Alzheimers Disease Drugs Market and Prevalence Analysis

6.1.1

United States - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.1.2

United States - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

6.2

France - Alzheimers Disease Drugs Market and Prevalence Analysis

6.2.1

France - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.2.2

France - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.3

Germany - Alzheimers Disease Drugs Market and Prevalence Analysis

6.3.1

Germany - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.3.2

Germany - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.4

Italy - Alzheimers Disease Drugs Market and Prevalence Analysis

6.4.1

Italy - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.4.2

Italy - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.5

Spain - Alzheimers Disease Drugs Market and Prevalence Analysis

6.5.1

Spain - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.5.2

Spain - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.6

United Kingdom - Alzheimers Disease Drugs Market and Prevalence Analysis

iGATE Research

Page 9 of 17

www.igateresearch.com

6.6.1

United Kingdom - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.6.2

United Kingdom - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.7

6.7.1

Japan - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.7.2

Japan - Alzheimers Disease Prevalence and Forecast (2012 - 2020)

6.8

8.

9.

China - Alzheimers Disease Drugs Market and Prevalence Analysis

6.8.1

China - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.8.2

China - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

6.9

7.

Japan - Alzheimers Disease Drugs Market and Prevalence Analysis

India - Alzheimers Disease Drugs Market and Prevalence Analysis

6.9.1

India - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)

6.9.2

India - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

Global Alzheimers Disease Drugs Market - Major Deals Analysis

7.1

Global Alzheimers Disease Drugs Market - Strategic Alliance

7.2

Global Alzheimers Disease Drugs Market - Licensing Agreement

7.3

Global Alzheimers Disease Drugs Market - Collaboration Deals

7.4

Global Alzheimers Disease Drugs Market - Mergers and Acquisitions

Global Alzheimers Disease Drugs Research - Funding Analysis

8.1

National Institute of Health (2011 - 2016)

8.2

Alzheimer's Association (2011 - 2014)

8.3

Cure Alzheimers Fund (2008 - 2014)

8.4

Alzheimers Drug Discovery Foundation (2008 - 2013)

8.5

BrightFocus Foundation (2010 - 2014)

Global Alzheimers Disease Drug Market - Driving Factors

9.1

Growing Aging Population

9.1.1

Global Ageing Indicators

9.1.2

Population Aged 60 or Over: World and Development Regions, 1950 - 2050

9.1.3

Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 -

2050
9.2

Unmet Medical Needs

9.3

Strong Pipeline Candidate Expected to Drive Alzheimers Disease Drugs Market

iGATE Research

Page 10 of 17

www.igateresearch.com

9.4

Future Drugs for Disease Modification in Alzheimers Disease

Global Alzheimers Disease Drug Market - Challenges

10.
10.1

Lack of Validated Targets & Lack of Animal Models

10.2

Barriers in the Design and Implementation of Clinical Trials

10.3

Barriers in Academia & Regulatory Issues

10.4

Alzheimers Drug Failure: Insinuation for Future R&D in Neuroscience

10.5

Costly Alzheimers Drug Development Dissuade Drug Companies

10.6

Research Setbacks and Stepping Stones

10.7

Country Wise Barriers to Growth for Alzheimers Disease Drugs Market

10.7.1

Unite States

10.7.2

France

10.7.3

Germany

10.7.4

United Kingdom

10.7.5

Japan

10.7.6

China

10.7.7

India

iGATE Research

Page 11 of 17

www.igateresearch.com

List of Figures:
Figure 2-1: Global - Alzheimers Disease Drugs Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 2-3: Global - Alzheimers Disease Prevalence (Million), 2010 - 2014
Figure 2-4: Global - Forecast for Alzheimers Disease Prevalence (Million), 2015 - 2020
Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2014
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2015 - 2020
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2014
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2015 - 2020
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2014
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2015 - 2019
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2014
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2015 - 2020
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2014
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2015 - 2019
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2014
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2015 - 2020
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2014
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2015 - 2020
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2014
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2015 - 2020
Figure 4-17: Global - Forecast for Namzaric Drugs Sales (Million US$), 2015 - 2020
Figure 5-1: Global - Forecast for Solanezumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-2: Global - Forecast for ABT-126 Drugs Sales (Million US$), 2017 - 2020
Figure 5-3: Global - Forecast for Idalopirdine Drugs Sales (Million US$), 2017 - 2020
Figure 5-4: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-5: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2018 - 2020
Figure 5-6: Global - Forecast for Lu AE58054 Drugs Sales (Million US$), 2017 - 2019
Figure 5-7: Global - Forecast for BIIB037 Drugs Sales (Million US$), 2019 - 2020
Figure 6-1: United States - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-2: United States - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-3: United States - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-4: United States - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-5: France - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-6: France - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020

iGATE Research

Page 12 of 17

www.igateresearch.com

Figure 6-7: France - Alzheimers Disease Prevalence (Thousand), 2012 - 2014

Figure 6-8: France - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-9: Germany - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-10: Germany - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-11: Germany - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-12: Germany - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-13: Italy - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-14: Italy - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-15: Italy - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-16: Italy - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-17: Spain - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-18: Spain - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-19: Spain - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-20: Spain - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-21: United Kingdom - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-22: United Kingdom - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-23: United Kingdom - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
Figure 6-24: United Kingdom - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-25: Japan - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-26: Japan - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-27: Japan - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-28: Japan - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-29: China - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-30: China - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-31: China - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-32: China - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 6-33: India - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-34: India - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-35: India - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
Figure 6-36: India - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
Figure 8-1: National Institute of Health - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
Figure 8-2: National Institute of Health - Forecast for Alzheimers Disease Research Funding (Million US$),
2015 - 2016
Figure 8-3: Alzheimers Association - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
Figure 8-4: Cure Alzheimers Fund - Alzheimers Disease Research Funding (Million US$), 2008 - 2014

iGATE Research

Page 13 of 17

www.igateresearch.com

Figure 8-5: Alzheimers Drug Discovery Foundation - Alzheimers Disease Research Funding (Million US$),
2008 - 2013
Figure 9-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009,
2025 & 2050
Figure 9-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 9-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
Figure 9-4: Global - Forecast for Alzheimers Disease Pipeline Drugs Market (Million US$), 2017 - 2020
Figure 10-1: Unsuccessful Alzheimers Drug Development (Number), 1998 - 2011

iGATE Research

Page 14 of 17

www.igateresearch.com

List of Tables:
Table 3-1: Country Wise - Alzheimers Disease Drugs Market Share (Percent), 2013 - 2014
Table 3-2: Country Wise - Forecast for Alzheimers Disease Drugs Market Share (Percent), 2015 - 2020
Table 7-1: Global Alzheimers Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 7-2: Global Alzheimers Disease Drugs Market - Licensing Agreement, 2007 - 2015
Table 7-3: Global Alzheimers Disease Drugs Market - Collaboration Deals, 2005 - 2015
Table 7-4: Global Alzheimers Disease Drugs Market - Mergers and Acquisitions, 2008 - 2015
Table 8-1: BrightFocus Foundation - Alzheimers Disease Research Funding (Million US$), 2010 - 2014
Table 9-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 9-2: Global - Population (Number), 2011/2012 - 2050
Table 9-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium
Variant)

iGATE Research

Page 15 of 17

www.igateresearch.com

Order the Report

Report Title: Global Alzheimers Disease Drugs Market and Pipeline Drugs Market
Analysis to 2020
To Order the Report Visit:
http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Alzheimers%20Disease%
20Drugs%20Market%20Analysis

Single User License

US$ 1,100

Hard-copy Mail Delivery

US$ 1,250

CD-ROM Mail Delivery

US$ 1,200

Multi User License

US$ 1,600

For More Details Visit:

http://www.igateresearch.com/

iGATE Research

Page 16 of 17

www.igateresearch.com

Contact US
iGATE RESEARCH PVT. LTD.
Web: www.igateresearch.com
To order the Report:
E-Mail: info@igateresearch.com
Contact No. : +91-858-684-0791, +91-706-527-9335/9336 (INDIA)
For Report Related Query:
E-Mail: ravi.sinha@igateresearch.com
Contact No. : +91-858-684-0791, +91-706-527-9335 (INDIA)

Follow US

Facebook: https://www.facebook.com/pages/IGATE-Research/1569079456648005?sk=timeline
Twitter: https://twitter.com/IgateResearch
You Tube: https://www.youtube.com/channel/UCOr7KNn4JfTwk5_kQjj-xrQ
Google+: https://plus.google.com/110560526954506242845/posts
Linkedin:https://www.linkedin.com/profile/view?authType=NAME_SEARCH&locale=en_US&id=
374611590&trk=tyah&trkInfo=tarId%3A1414504898315%2Ctas%3Aigate+research%2Cidx%3A1-11&authToken=YgR7

iGATE Research

Page 17 of 17

www.igateresearch.com